Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Amgen to launch US Eylea biosimilar
Regeneron loses bid to block Amgen's Eylea biosimilar launch in US
Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling in its favor on Tuesday, an Amgen spokesperson said. The U.S. Court of Appeals for the Federal Circuit rejected Regeneron's request to block the launch during its appeal of a related decision for Amgen in a patent case in West Virginia.
Legal win leads Amgen to at-risk launch of Eylea biosimilar
Amgen's move follows the lifting of a temporary injunction on the launch of its Pavblu-branded biosimilar by the US Court of Appeals for the Federal Circuit, which prompted the company to say it would launch "as quickly as possible to help expand access to affordable and effective treatment."
Amgen plans launch of Eylea biosimilar after court ruling
With “nerves of steel,” Amgen is getting ready to sell a copycat of Regeneron’s top-selling eye drug Eylea, even as litigation continues.
Amgen to launch US Eylea biosimilar after ruling in Regeneron patent case
Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling in its favor on Tuesday, an Amgen spokesperson said. The U.S. Court of App
Cautious Hold Rating for Regeneron Amidst Competitive Threat from Amgen’s Eylea Biosimilar
Robert W. Baird analyst Brian Skorney maintained a Hold rating on Regeneron (REGN – Research Report) on October 22 and set a price target
District Court Denies Regeneron’s Motion For Preliminary Injunction To Block Amgen’s Eylea Biosimilar
On September 23, 2024, Judge Kleeh of the Northern District of West Virginia denied Regeneron Pharmaceuticals, Inc.’s (“Regeneron”) motion for
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
To request a FREE 2-week trial subscription, please signup. NOTE - this can take up to 48hrs to be approved.
RBC would buy Regeneron on weakness with biosimilar Eylea priced in
RBC Capital notes that it was announced that the Court of Appeals denied Regeneron’s (REGN) motion for an emergency injunction and the
FiercePharma
1d
Amgen pledges to launch Eylea biosim after legal win—but Regeneron stresses the fight's not over yet
While
Regeneron
may have lost its latest bid to block the launch of
Amgen
’s
Eylea
biosimilar Pavblu, the New York-based ...
12h
Regeneron: Buy Rating Reaffirmed Amid Eylea Biosimilar Challenge and Pipeline Strength
J.P. Morgan analyst Chris Schott maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,150.00.
STAT
1d
Pharmalittle: We’re reading about Novo targeting compounded obesity drugs, an Amgen ‘at risk’ launch, and more
Novo Nordisk asked the FDA to bar compounding pharmacies from making semaglutide, arguing it is too complex for the ...
FiercePharma
1d
Roche's Vabysmo will rise above Eylea biosim threat, exec says, as DMD gene therapy Elevidys delivers sales surprise
By squeezing Regeneron’s Eylea, eye disease drug Vabysmo has become one of the biggest growth drivers for Roche. | Despite ...
ENDPOINTS NEWS
2d
Amgen preps to launch Eylea biosimilar years early after Regeneron loses appeal
Amgen is moving forward with the launch of Pavblu, its biosimilar to Regeneron's blockbuster Eylea, following an appeals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback